Introduction
============

The systemic capillary leak syndrome (SCLS) is a very rare disorder of unknown etiology first described in 1960 by Clarkson.[@R1] The disease occurs sporadically, primarily in Caucasian adults, who experience acute, reversible attacks of hypotension and anasarca due to the loss of plasma volume into peripheral tissues, particularly to the extremities.[@R2] The diagnosis of SCLS is strictly clinical and is made on the basis of characteristic symptoms and evidence of decreased plasma volume (hemoconcentration) and protein loss from the intravascular space (hypoalbuminemia) during acute episodes.[@R3] Although SCLS is probably underreported due to the difficulty of diagnosis and its resemblance to more prevalent diseases such as sepsis and systemic anaphylaxis, fewer than 250 cases have been reported since its original description in 1960. Trigger(s) for attacks are often not apparent, and most patients are asymptomatic between episodes. Treatment of acute disease is primarily supportive (IV fluids, vasopressors); more recently intravenous immunoglobulin (IVIG) administered on a monthly basis has shown promise in reducing the frequency and severity of SCLS episodes.[@R4]^,^[@R5]

The pathogenesis of SCLS is unknown. Although 85--95% of patients with SCLS also have MGUS, a plasma cell dyscrasia characterized by the presence of a serum monoclonal immunoglobulin (typically IgG), the reactivity of this "paraprotein" and its role in the disease are unknown. In a recent study that included 23 patients with confirmed SCLS, we found elevated levels of canonical mediators of endothelial hyperpermeability (VEGF and Ang2) in episodic sera only.[@R6] Likewise, acute sera induced hyperpermeability of human microvascular endothelial cell (HMVEC) monolayers in functional assays.[@R6] These results suggest that circulating blood factors induce the clinical symptoms of SCLS by inciting transient hyperpermeability in the microvasculature of peripheral extremities.

Because of the rarity of the disease and the paucity of reported cases, it is not possible to accumulate adequate numbers of SCLS patients for a genome-wide association study. However, new cost-effective technologies such as microarray SNP-chip typing and whole exome sequencing (WES) allowed us to identify candidate genes, mutations, and potential targets for further study and validation.[@R10] We performed a genome-wide SNP analysis using SNP-chips on 12 SCLS patients and 18 controls. Exome capture sequencing was done using genomic DNA from nine of the patients for validation of these SNPs and for discovery of SNPs not present on the SNP-chips. Interestingly, we found haplotypes significantly associated with SCLS, whose annotated functions provide insight into our previous mechanistic studies of SCLS sera. These preliminary findings provide the basis for further experiments to characterize the genetic factors responsible for SCLS susceptibility and disease.

Results
=======

SNPs associated with SCLS by SNP-chip analysis
----------------------------------------------

Our study cohort included 12 patients with SCLS. The control group consisted of 15 age, sex and ethnicity-matched healthy donors, two relatives of SCLS patients, and a reference sample supplied by the SNP-chip manufacturer (Affymetrix), which was from a Caucasian male of unknown age. 33% of the patient group (n = 4) and 44% (n = 8) of the control group were female ([Table 1](#T1){ref-type="table"}). The mean ages of the case and control subsets at the time of sample collection were not significantly different (median age 52.5 y \[range 40--67\] and 49 y \[range 19--67\], respectively) (*P* = 0.07). Consistent with the demographics of SCLS, 100% of the disease group was Caucasian, as was 89% of the control group (16 of 18).

###### **Table 1.** Characteristics of study population

                                              [Disease (n = 12)\*]{.ul}   [Controls (n = 18)]{.ul}
  ------------------------------------------- --------------------------- --------------------------
  Males                                       8                           10
  Females                                     4                           8
  Mean age at enrollment (years ± S.D.)\*\*   53.8 ± 6.9                  46.5 ± 13.8\*\*\*
  Caucasian                                   12                          16^&^
  Classic acute SCLS                          11                          NA
  Chronic SCLS                                1                           NA
  MGUS                                        10 (83%)                    NA

Diagnosis of SCLS made according to established criteria: at least one episode of hypotension, hemoconcentration (elevated Hgb/Hct), and hypoalbuminemia or chronic edema and hypoalbuminemia; \*\**P* = 0. 07, Mann-Whitney test;\*\*\*does not include reference sample; ^&^includes 1 Hispanic, 1 African-American.

After quality control, 873,246 SNPs across 24 chromosomes in 12 SCLS and 18 control subjects were discovered. 23,652 SNPs had association *P* values less than 0.05 by Fisher's exact test ([Fig. 1A](#F1){ref-type="fig"}). Because our studies were limited by the small number of patients with SCLS, we set an initial threshold for genome-wide significance of less than 10^−3^ by Chi-square test and analyzed variants meeting this criterion in further detail. A total of 653 SNPs in 134 genes had association *P* values of less than 10^−3^, and 74 SNPs had *P* values of 10^−4^ or less by PLINK analysis. Six of the 653 SNPs were exonic, three of which encoded non-synonymous mutations. Nine SNPs were located upstream or downstream of coding sequences potentially within regulatory regions while the majority of these SNPs were intronic or intergenic ([Fig. 1B](#F1){ref-type="fig"}).

![**Figure 1.** Genome-wide analysis of 875,967 SNPs in 12 cases of SCLS and 18 control subjects. (**A**) Manhattan plot showing negative log-transformed *P* values of the case-control allele frequency significance on the *y*-axis. The color scale of the *x*-axis denotes chromosome numbers. Gene names associated with individual dots indicate SNPs of greatest significance or with potential disease relevance. (**B**) Distribution of 653 SNPs meeting the established criterion for genome-wide significance (*P* ≤ 1 × 10^−3^, Chi square test). (**C**) Expanded view of chromosomes 6--7, which contain regions of neighboring SNPs highly associated with SCLS.](rdis-1-e27445-g1){#F1}

Several of the most highly ranked SNPs associated with SCLS are presented in [Table 2](#T2){ref-type="table"}. SNPs located in genes with unknown functions or without obvious importance to disease pathogenesis are not discussed here. Nonetheless, SNPs were detected in genes with potential relevance to SCLS by virtue of their known or suspected functions in endothelial cell signaling, adhesion, or barrier function. For example, rs12355803 (*P* = 8.38 × 10^−5^, OR 13) and rs4436485 (*P* = 2.88 × 10^−4^, OR 9.46) were two highly ranked SNPs in *BTRC* (10q24.32). This gene encodes β transducin repeat-containing E3 ubiquitin protein ligase, βTRCP, a proteasomal factor implicated in inflammation and in growth factor receptor recycling, as discussed further below.[@R11]^,^[@R12] Two SCLS-associated SNPs were discovered in *AFAP1* (rs6446627 and rs7682611; both with *P* = 4.1 × 10^−4^, OR 21). *AFAP1* encodes actin filament binding protein one hundred and ten (AFAP110), a Src-phosphorylated adaptor that regulates growth factor-induced actin stress fiber formation and adhesion.[@R13] We also identified SNPs in introns of membrane-associated proteins related to endothelial cell growth and/or permeability such as rs919751 in *PDGFRB* (*P* = 2.7 × 10^−4^, OR 8.33) and rs4782779 in *CDH13* (*P* = 7.67 × 10^−4^, OR 9.31) ([Table 2](#T2){ref-type="table"}). A trio of SNPs in *EDG2*, which encodes lysophosphatidic acid (LPA) receptor one (LPAR1), was detected only in SCLS cases with a case allelic frequency of 0.29 (rs12552348, rs1326890, rs2025766; *P* = 5.65 × 10^−4^).

###### **Table 2.** Highly ranked SNPs associated with SCLS

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [SNP]{.ul}   [Gene]{.ul}      [Chromosome]{.ul}   [bp\*]{.ul}   [location]{.ul}   [Minor allele (case frequency)]{.ul}   [OR (95% CI)]{.ul}   *[P]{.ul}*[value\*\*]{.ul}
  ------------ ---------------- ------------------- ------------- ----------------- -------------------------------------- -------------------- ----------------------------
  rs6417039    *LOC100130480*   18                  6568416       intron            A (0.54)                               41.4 (4.8--352.9)    4.2 × 10^−6^

  rs3917490    *PON1*           7                   94948841      intron            T (0.75)                               12.4 (3.6--42.9)     1.9 × 10^−5^

  rs3130981    *CDSN*           6                   31083813      exon\             T (0.58)                               15.4 (3.7--64.6)     2.6 × 10^−5^
                                                                  (N527D)                                                                       

  rs12489170   *PARP15*         3                   122354792     exon (G394R)      A (0.38)                               NA\*\*\*             6.8 × 10^−5^

  rs12355803   *BTRC*           10                  103176449     intron            A (0.54)                               13 (3.1--54.3)       8.4 × 10^−5^

  rs10239315   *CHCHD3*         7                   132672067     intron            C (0.71)                               8.5 (2.6--27.7)      1.8 × 10^−4^

  rs919751     *PDGFRB*         5                   149505489     intron            G (0.63)                               8.3 (2.5--27.8)      2.7 × 10^−4^

  rs11668246   *ARHGEF18*       19                  7492991       intron            A (0.63)                               8.7 (2.5--30.2)      2.9 × 10^−4^

  rs2364281    *KBTBD8*         3                   67050203      intron            T (0.71)                               7.3 (2.3--23.2)      4.5 × 10^−4^

  rs12552348   *EDG2*           9                   113705204     intron            T (0.29)                               NA                   5.7 × 10^−4^

  rs4782779    *CDH13*          16                  83402943      intron            A (0.46)                               9.3 (2.2--38.9)      7.7 × 10^−4^

  rs12911414   *RASGRF1*        15                  79343534      intron            G (0.58)                               7 (2.1--23.1)        7.9 × 10^−4^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GRCh37.p5 assembly;\*\*Chi-square test; \*\*\*Not applicable, detected only in cases.

Whole exome sequencing
----------------------

We performed exome capture sequencing to validate the SNP-chip data and to discover SNPs not present on the array. Cost considerations limited this analysis to the first nine patients enrolled in the study. Based on WES data alone, we discovered 10, 955 SNPs that were detected in all nine patients tested. We compared data across the two technologies and found a total of 1,416 SNPs in common. 61 of these SNPs were significantly associated with SCLS based on PLINK analysis of the SNP-chip data (*P* \< 0.05, Chi square test). Ten of the SCLS-associated SNPs encoded exonic, nonsynonymous mutations whereas 23 variants encoded exonic, synonymous mutations. The remaining 28 SNPs were located in intronic, untranslated, or intergenic regions. Several of the top ranked SNPs detected by both methods are presented in [Table 3](#T3){ref-type="table"}. This subset included SNPs in genes involved in protein degradation and/or the proteasome (*SERPINB1, CPN1, CTSL1, KLK7, PSMB3*). In particular, deficiency of carboxypeptidase 1 (encoded by *CPN1*), which is a proteolytic inactivator of serum kinins and anaphylatoxins, has been associated with increased susceptibility to C5a-mediated anaphylactic shock in mice, which is a clinical phenotype that closely resembles SCLS.[@R14] Functional annotation of SNPs present in both SNP-chip and WES also revealed genes involved prominently in cell-cell junctions and adhesion (*MYOF, DSG4, SIGLEC12, SLC24A3*), suggesting potential impact on the endothelial barrier dysfunction that characterizes SCLS.

###### **Table 3.** SCLS associated SNPs detected by both exome sequencing and SNP array

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [SNP]{.ul}   [Gene]{.ul}   [Chromosome]{.ul}   [bp\*]{.ul}   [location]{.ul}   [Minor allele (case frequency)]{.ul}   [OR (95% CI)]{.ul}   *[P]{.ul}*[value\*\*]{.ul}
  ------------ ------------- ------------------- ------------- ----------------- -------------------------------------- -------------------- ----------------------------
  rs386915     *SERPINB1*    6                   2834265       intron            C (0.125)                              0.16 (0.04--0.63)    5.2 × 10^−3^

  rs228274     *PSMB3*       17                  36909061      5UTR^\#^          A (0.083)                              0.161 (0.03--0.79)   0.015

  rs1569767    *SLC24A3*     20                  19261623      exon\             A (0.583)                              3.64 (1.22- 10.8)    0.018
                                                               (V55I)                                                                        

  rs10883439   *CPN1*        10                  101841153     intron            A (0.208)                              9.21 (1--84.7)       0.022

  rs1614065    *MYOF*        10                  95097537      intron            T (0.167)                              0.25 (0.07--0.88)    0.025

  rs3752135    *SIGLEC12*    19                  52000624      exon\             T (0.25)                               5.67 (1.03--31)      0.03
                                                               (Y376S)                                                                       

  rs4799570    *DSG4*        18                  28986333      exon\             A (0.375)                              3.72 (1.06--13.05)   0.034
                                                               (I644L)                                                                       

  rs2274611    *CTSL1*       9                   90342675      intron            T (0.667)                              3.14 (1.07--9.27)    0.035

  rs12185460   *ARHGAP28*    18                  6898415       intron            C (0.292)                              0.329 (0.11--0.99)   0.044
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

GRCh37.p5 assemby; \*\*Chi-square test; ^\#^5′ untranslated region

We determined the possible ramifications of amino acid changes conferred by SNPs discovered in the SNP-chip and WES data using the PolyPhen software algorithm. Of the three SNPs in the SNP-chip data set associated with non-synonymous exonic mutations, those in *PARP15* and *OR5A2* resulted in potentially deleterious amino acid changes, as shown in [Table 4](#T4){ref-type="table"}. Nine of ten non-synonymous exonic mutations detected by both WES and SNP-chip were classified as benign whereas rs8181512 in *OR52N2* is predicted to lead to a damaging amino acid change (H791R) in an olfactory receptor.

###### **Table 4.** Impact of non-synonymous mutations detected by SNP-chip and/or WES

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  [SNP]{.ul}   [Protein]{.ul}   [Mutation]{.ul}   [Frequency by WES (\# positive/total)]{.ul}   [PolyPhen annotation]{.ul}\   *[P]{.ul}*[value]{.ul}
                                                                                                [(score)]{.ul}                
  ------------ ---------------- ----------------- --------------------------------------------- ----------------------------- ------------------------
  rs3130981    CDSN             N527D             0/9                                           benign (0.004)                2.6 × 10^−5^

  rs12489170   PARP15           G394R / G628R\*   4/9                                           probably damaging (1.0)       6.7 × 10^−5^

  rs1453547    OR5A2            P172L             7/9                                           probably damaging (0.997)     8.5 × 10^−4^

  rs8181512    OR52N2           H791R             9/9                                           probably damaging (0.991)     4 × 10^−3^
  ----------------------------------------------------------------------------------------------------------------------------------------------------

alternative splice variants; \*\*Chi-square test

Functional annotation of SCLS-associated variants
-------------------------------------------------

We analyzed the 134 genes containing 653 SNPs significantly associated with SCLS by SNP-chip analysis using the DAVID functional clustering algorithm ([Table 5](#T5){ref-type="table"}). This study revealed enrichment of genes related to endothelial barrier function including those involving cell projections, cell adhesion, cell junctions, and synapses ([Fig. 2A and B](#F2){ref-type="fig"}). Functional categories enriched at least 2-fold in this subset included cell adhesion (3.3-fold, *P* = 5.5 × 10^−3^) and cell junctions (3.9-fold, *P* = 1 × 10^−3^). Several gene ontology terms were enriched including regulation of Rho signal transduction (6.6-fold, *P* = 6.9 × 10^−3^), biological and cell adhesion (2.4-fold, *P* = 6.8 × 10^−3^), cadherin binding (23.6-fold, *P* = 6.8 × 10^−3^), and cell adhesion molecule binding (13.4-fold, *P* = 0.02). Additional functional and network evaluation using IPA revealed enrichment of functional categories including cell-to-cell signaling and interaction and cellular assembly and maintenance ([Fig. 3](#F3){ref-type="fig"}). These enriched categories were closely related to the mechanisms implicated by our previous functional studies of SCLS sera, as discussed below.

###### **Table 5.** Functional enrichment analysis of top ranked SNPs

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [Annotation terms]{.ul}                                            [Enrichment score]{.ul}   [\#Genes\*]{.ul}   [Fold enrichment\*]{.ul}   [Select clustered genes]{.ul}                                                                         *[P]{.ul}*[value\*\*]{.ul}
  ------------------------------------------------------------------ ------------------------- ------------------ -------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------
  cell projection organization, neuron projection, cell projection   3.26                      13                 4.6                        *ATP2B2, NCK2, RASGRF1, DSCAM, CDH13, CTNNA2, CHRM3, KALRN, LPAR1*                                    2.3 × 10^−5^

  synapse, cell junction, postsynaptic cell membrane                 2.64                      11                 4                          *AFAP1, CTNNA2, CHRM3, CDSN, GRID1, GRIK1*                                                            3.9 × 10^−4^

  plasma membrane (part, integral, intrinsic)                        2.6                       34                 2                          *ATP2B2, DSCAM, AFAP1, ADCY3, CDH13, CTNNA2, CHRM3, CDSN, EMCN, ITGA9, GNA14, LPAR1, PDGFRB, TRPA1*   4.6 × 10^−5^

  pleckstrin homology domain, Rho and Ras regulation, RhoGEF         2.43                      5                  21                         *ARAP1, ASAP2, RASGRF1, ARHGEF18, AFAP1, ADCY3, BTRC, DGKB, KALRN, LPAR1, PON1*                       8.9 × 10^−5^

  fibronectin type III domain,\                                      2.35                      8                  3.88                       *ADAMTSL1, CNTN3, NEO1, PDGFRB, PTPRD, ITGA9, CDH13, PCDH15, PCDH19*                                  1.4 × 10^−4^
  immunoglobulin domain Ig-like C2 (types 1--2),                                                                                                                                                                                                   

  cell adhesion, biological adhesion, cell-cell adhesion             2.19                      9                  3.3                        *DSCAM, CDH13, CTNNA2, CNTN3, CDSN, EMCN, ITGA9*                                                      5.5 × 10^−3^
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For top cluster term; \*\*EASE score (modified Fisher\'s exact test) for top cluster term

![**Figure 2.** Functional enrichment of SCLS-associated SNPs. (**A, B**) 2-D heat maps representing genes containing SNPs significantly associated with SCLS and their associated functional annotation terms, as determined by the DAVID software algorithm. Related genes are portrayed on the *x*-axis and their corresponding annotations on the *y*-axis. Green areas represent positively reported gene-term association whereas black areas denote no gene-term association yet reported. Functionally enriched categories related to endothelial barrier dysregulation in SCLS included "cell projections" (**A**) and "cell adhesion" (**B**).](rdis-1-e27445-g2){#F2}

![**Figure 3.** IPA network analysis reveals association of genes related to cytoplasmic/cytoskeletal organization. A list of 134 genes containing 653 SNPs associated with SCLS were uploaded for core analysis using Ingenuity Pathways Knowledge Base as reference. The network has been simplified for clear illustration of genes of interest. Colored symbol are genes contained on the list. Symbol shapes correspond to molecular functions as indicated. Direct or indirect interactions are shown by complete or dashed lines, respectively](rdis-1-e27445-g3){#F3}

Discussion
==========

SCLS is a rare disorder of unknown etiology that causes substantial morbidity and mortality to those affected. During an acute SCLS attack, patients may present in hypotensive shock due to the loss of up to 70% of their plasma volume into the tissues. Life-threatening complications result from hypovolemia and/or hypoperfusion (renal failure, stroke), increased serum viscosity (thrombosis), increased pressures in the edematous upper and lower extremities (compartment syndromes), and heart failure due to the recruitment of fluids into the intravascular compartment during the post-leak phase associated with the acute SCLS episode. Our previous research demonstrated that application of acute SCLS sera to normal HMVECs induced barrier breakdown, suggesting that exogenous factors present in acute SCLS sera induce the transient clinical symptoms of vascular leak. Accordingly, we found elevated levels of endothelial permeability mediators, VEGF and Ang2, in acute, but not baseline, SCLS sera. However, key questions remain. What are the cellular sources of these mediators, and what is the trigger for their secretion? Do primary genetic abnormalities in endothelial cells of SCLS subjects induce aberrant responses to VEGF, Ang2, or other factors? Does the monoclonal IgG present in SCLS sera elicit the endothelial hyperpermeability associated with acute SCLS episodes, either directly or indirectly?

A significant obstacle in addressing these questions is the extreme rarity of the disease. Currently, worldwide prevalence is estimated to be \~50--100 cases with a confirmed diagnosis. In spite of these challenges, we performed the first genome-wide SNP and exome-capture sequencing analysis of an SCLS cohort to uncover potential genetic abnormalities associated with the disease. Our pilot study identified haplotypes significantly associated with the SCLS trait and several candidate susceptibility loci. Most strikingly, functional annotation of SCLS-associated SNPs revealed significant enrichment of cell junctions, cell-to-cell interactions, Rho-Rac signaling, and adhesion, among others, which are cellular constituents or processes that affect formation and maintenance of the vascular barrier.

We found previously that SCLS sera induced endothelial barrier disruption through internalization of the membrane junctional protein VE-cadherin.[@R6] Our functional annotation of SNP-chip data suggests that gene polymorphisms present in SCLS patients could lead to intrinsically abnormal endothelial responses to known permeability mediators. As but one example, rs4782779 in *CDH13* was strongly associated with SCLS. *CDH13* encodes T-cadherin, a glycophosphatidyloinositol (GPI)-linked junctional adhesion protein whose physiological functions include protecting endothelial cells from reactive oxygen species (ROS)-induced damage. In published study, SCLS sera elicited endothelial production of ROS, which are known to induce vascular hyperpermeability,[@R15]^,^[@R16] suggesting that mutations in *CDH13* could affect endothelial responses to oxidative stress in this disorder.

We also discovered SNPs in genes that could lead to impaired responses to VEGF, a permeability mediator present in increased amounts in acute SCLS sera. rs12355803 and several other SNPs in *BTRC* were detected in the SCLS group. *BTRC* encodes βTRCP, the F box protein component of SCF (SKP1-cullin-F-box) ubiquitin protein ligase complex.[@R17]^,^[@R18]^,^[@R19] A published study demonstrated that βTRCP promoted ubiquitylation and degradation of the endothelial VEGF receptor (VEGFR2), and βTRCP knockdown enhanced VEGFR2 signaling.[@R12] We also detected a disease-associated SNP (rs1614065) in *MYOF,,* which encodes dysferlin, an Ig C2 domain containing protein (also a functionally enriched category) that promotes endothelial cell adhesion by inhibiting VEGFR2 degradation.[@R20]^,^[@R21] Thus, polymorphisms in *BRTC* and/or *MYOF* could affect responses to VEGF in SCLS patients through modulation of VEGFR2 expression.

Our prior mechanistic studies revealed that acute SCLS sera induced endothelial retraction through actin-stress fiber formation and cell morphological changes. Canonical permeability mediators such as VEGF and Ang2 induce actin polymerization and cytoskeletal rearrangement by activating Rho- and Rac-dependent signaling pathways.[@R22] We detected SCLS-associated SNPs in *ARAP1,* which encodes a PH domain-containing RhoGAP,[@R23] in *KALRN*, encoding a RhoGEF with kinase activity,[@R24] and in *EDG2*, which encodes LPAR1. All three gene products may affect endothelial barrier function through Rho-Rac activation.[@R25]

Finally, we detected SCLS associated SNPs in genes potentially related to the clonal plasma cell expansion that typifies MGUS.[@R26]^-^[@R32] A trio of SNPs in *PARP15* (3q21) had an allelic frequency of 0.33 in SCLS patients, but was not detected in the control group. PARP15 is a transcriptional repressor associated with B cell lymphoma.[@R33] One such SCLS-associated SNP in *PARP* discovered by the SNP-chip analysis (rs12489170) was also detected in 4 of 9 patients by WES, at a frequency of 42--100%. Because this SNP encodes a damaging missense mutation in the PARP15 protein (G394R or G628R depending on the splice variant), further examination of *PARP15* sequence in the SCLS cohort may be warranted.

Although our SNP analysis points to disease associations with a number of gene variants, the contribution of hereditary factors to the SCLS phenotype is currently unknown.[@R34]^,^[@R35] Most SCLS patients are adults with no family history of disease, who manifest symptoms in mid-life. A Jewish family with familial SCLS was reported in 2010.[@R36] The index case was an eight-year old boy with repeated attacks of hypotensive shock accompanied by hemoconcentration and hypoalbuminemia consistent with the diagnosis of SCLS. However, the sparse family history provided makes it unclear whether this patient and his family had vertically transmitted SCLS or a variant of the disorder that was originally described by Clarkson. Further approaches such as whole genomic sequencing or RNA-Seq of plasma cell- or endothelial cell-enriched sources (e.g., bone marrow or blood-outgrowth endothelial cells) could reveal the presence of acquired somatic mutations in adult SCLS patients.

In summary, we performed a genome-wide SNP analysis of a poorly studied disorder, SCLS. We discovered polymorphisms in genes whose functional annotations suggest involvement in cell-cell junctions and signaling, cell adhesion, and cytoskeletal organization, which correlate with our previous mechanistic studies of SCLS sera. Such annotations provide a framework for future allelic discrimination strategies to validate top ranked SNPs discovered here as well as novel SNPs unique to the SCLS cohort detected by exome capture sequencing. We stress that although this is a preliminary survey, our study will facilitate the acquisition of research funds that will allow for an in-depth genetic survey of more patients, using more expensive technology such as whole genomic sequencing. This paper, which focuses on genetic characterization of a rare and unusual disease, is the first effort of its kind for SCLS. Although our findings must be corroborated in a larger cohort, they provide a springboard for discovery of underlying pathophysiological mechanisms, biomarkers, and avenues for therapy.

Patients, Methods, and Materials
================================

Study subjects
--------------

SCLS patients were included in the study based upon meeting the following established clinical criteria: at least one episode of reversible hypotension, hemoconcentration, and hypoalbuminemia, or chronic edema and hypoalbuminemia in the absence of secondary causes.[@R2]^,^[@R4] All patients were seen at the Clinical Center of the National Institutes of Health. Written informed consent was obtained from each patient, and the study protocol (09-I-0184) conformed to the ethical guidelines of the 2008 Declaration of Helsinki as reflected in a priori approval from the Institutional Review Board of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). Age-, sex-, and ethnicity-matched blood samples were obtained from the NIH Blood Bank.

DNA isolation and SNP array
---------------------------

Mononuclear cells were isolated from patient and healthy control human peripheral blood samples using Lymphocyte Separation Medium (MP Biomedicals). Because a high proportion of patients with SCLS have MGUS, which indicates that chromosomal mutations or translocations may have occurred during early B lineage development, we used purified B lymphocytes for genome-wide SNP analysis. B cells were isolated from peripheral blood during flow sorting using anti-CD19 antibody (BD Biosciences). DNA targets from patients and healthy controls were prepared and hybridized to Affymetrix Genome-Wide Human SNP array 6.0 chips following the manufacturer's recommendations. Quality analysis was performed by importing the CEL files into Genotyping Console (GTC 4.0) according to the "Quality Control Assessment in Genotyping Console" (Affymetrix revision 1). An association analysis was performed for the control vs. case using PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/anal.shtml#cc>) software utilizing the Fisher's exact test, Chi-square and the estimated odds ratio. Pearson Chi square values and *P* values (Chi square and Fisher's exact test) were calculated using Haploview 4.2. PLINK data were deposited into GEO (Accession number GSE40495). The data can be viewed at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=lvsdbiagqmgewhi&acc=GSE49045>

Exome capture sequencing
------------------------

Genomic DNA was isolated from peripheral blood mononuclear cells of nine SCLS subjects and randomly digested into fragments with a length of approximately 150 to 200 base pairs (bp). Adapters were ligated to each end of the fragments, and adaptor-ligated templates were purified using Agencourt AMPure SPRI beads (Beckman Coulter). Purified DNA fragments were amplified by ligation-mediated polymerase chain reaction (LM-PCR), purified, and hybridized to the SureSelect Biotinylated RNA Library (BAITS) for enrichment (Agilent Technologies). The magnitude of enrichment of captured LM-PCR products was estimated using the Agilent 2100 Bioanalyzer. Each captured library was then loaded onto the Illumina Hiseq2000 sequencer. Whole exome sequence was obtained from all nine SCLS patients, with a mean target read depth of 54.19X, such that 88% of targeted reads had at least 10X coverage. Raw image files were processed by Illumina base calling Software 1.7 for base calling with default parameters, and the sequences of each individual were generated as 90 bp paired-end reads. Burrows-Wheeler Aligner was used to align sequences to the reference genome (GRCh37/hg19 assembly). SNPs were analyzed using *SOAPsnp*, and Small Insertion-Deletions (InDels) were detected by SAMtools. ANNOVAR was used to annotate variants. PolyPhen-2 (Polymorphism Phenotyping v2; <http://genetics.bwh.harvard.edu/pph2/>) software was used to predict possible impact of amino acid substitutions on the structure and function of individual proteins.

Functional annotation
---------------------

DAVID[@R7]^,^[@R8] and Enrichr[@R9] (<http://amp.pharm.mssm.edu/Enrichr/enrich>) algorithms, and Ingenuity Pathways Analysis (Ingenuity Systems) software tools were utilized for functional enrichment analysis and hierarchical clustering of SNPs detected by SNP Chip and/or whole exome sequencing. In DAVID, *P* values were calculated at medium classification stringency using a modified Fisher's exact test (EASE score), and terms with *P* values \< 0.05 were considered significantly enriched. ChIP Enrichment Analysis (ChEA, <http://amp.pharm.mssm.edu/lib/chea.jsp>) was used to analyze genome-wide transcription factor binding to trait-associated loci[@R9].
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Ang2

:   angiopoietin 2

MAF

:   minor allele frequency

VE-cadherin

:   vascular endothelial cadherin

GEF

:   guanine nucleotide exchange factor

GAP

:   GTPase activating protein

HDL

:   high density lipoprotein

LDL

:   low density lipoprotein

GWAS

:   genome-wide association studies

WES

:   whole exome capture sequencing
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